论文部分内容阅读
06年是公司经营业绩的拐点:除利卡汀之外,06年公司冻干滴眼用重组人表皮生产因子、伪狂犬病基因缺失疫苗都将上市,将扭转生物制药业务和动保制药业务亏损态势。预计公司06年、07年、08年业绩分别是0.19、0.33和0.73元,按照相应各部分业务的市场估值水平,其08年业绩对应股价应在7.5元以上。若考虑到目前10送3.2的对价方案,合理股价还应有30%以上的上升空间。
06 is the inflection point of the company’s operating performance: In addition to Likadin, the company in 2006 freeze-dried eye drops with recombinant human epidermal factor, pseudorabies gene deletion vaccine will be listed, will reverse the biopharmaceutical business and animal health insurance business loss situation. It is estimated that the performance of the Company in 2006, 2007 and 2008 will be 0.19, 0.33 and 0.73 Yuan respectively. According to the corresponding market valuation of each part of the business, its corresponding 2008 price should be above 7.5 Yuan. Taking into account the current 10 to send 3.2 price plan, a reasonable stock price should have more than 30% upside.